Augmenting energy delivery during the acute phase of critical illness may reduce mortality and improve functional outcomes. The objective of this sub-study was to evaluate the effect of early augmented enteral nutrition (EN) during critical illness, on outcomes one year later. We performed prospective longitudinal evaluation of study participants, initially enrolled in The Augmented versus Routine approach to Giving Energy Trial (TARGET), a feasibility study that randomised critically ill patients to 1.5 kcal/ml (augmented) or 1.0 kcal/ml (routine) EN administered at the same rate for up to ten days, who were alive at one year. One year after randomisation Short Form-36 version 2 (SF-36v2) and EuroQol-5D-5L quality of life surveys, and employment status were assessed via telephone survey. At one year there were 71 survivors (1.5 kcal/ml 38 versus 1.0 kcal/ ml 33; P=0.55). Thirty-nine (55%) patients consented to this follow-up study and completed the surveys (n = 23 and 16, respectively). The SF-36v2 physical and mental component summary scores were below normal population means but were similar in 1.5 kcal/ml and 1.0 kcal/ml groups (P=0.90 and P=0.71). EuroQol-5D-5L data were also comparable between groups (P=0.70). However, at one-year follow-up, more patients who received 1.5 kcal/ml were employed (7 versus 2; P=0.022). The delivery of 1.5 kcal/ml for a maximum of ten days did not affect self-rated quality of life one year later.
Nutrition administered via the enteral route to critically ill patients is considered an integral part of standard care 1 , yet the optimal amount of energy that should be provided is unknown. Numerous studies have reported that the provision of enteral nutrition (EN) to critically ill patients results in delivery of less energy than is currently recommended [2] [3] [4] [5] . Whilst observational studies report associations between less energy delivery and adverse outcomes [6] [7] [8] [9] there is an absence of high-quality prospective interventional trial data to establish causality.
A multicentre feasibility study (The Augmented versus Routine approach to Giving Energy Trial [TARGET]) endorsed by The Australian and New Zealand Intensive Care Society Clinical Trials Group (ANZICS CTG) was recently conducted to evaluate whether a 1.5 kcal/ml formula, when compared with a 1.0 kcal/ml formula, increased energy delivery 10 . In a double-blind fashion 112 mechanically ventilated patients were randomised to receive either an energy-dense EN formula (1.5 kcal/ml) to augment energy delivery, or routine care (1 kcal/ml), for a maximum of ten days. During the first ten days of EN the 1.5 kcal/ml group received 46% more energy 10 . Ninety days after enrolment in TARGET there were 79 survivors (1.5 kcal/ml n=45 versus 1.0 kcal/ml n=34) 10 .
There is increasing recognition that longitudinal outcomes are required to provide a more comprehensive understanding of the effectiveness of interventions during critical illness [11] [12] [13] . A recent study that randomised patients to either so-called 'trophic' or standard EN for a maximum of five days in an open-label fashion reported that trophic feeds did not improve functional recovery at 12 months after randomisation 11, 12 . These studies were considerably informative as substantial physical deficits were recorded in survivors of critical illness, indicating a need to evaluate the interaction between acute nutrient delivery and longitudinal outcomes.
At day 90 there were numerically more survivors who received the 1.5 kcal/ml formula but this may have been due to survival of those with the least capacity to recover and, therefore, greater limitations in physical deficits and participation at 12 months. Alternatively, increasing energy intake with the use of 1.5 kcal/ml formula early during critical illness may improve participation in rehabilitation and thereby ameliorate physical deficits and improve participation one year later 1, 14 . Obtaining a greater appreciation of retention rates and resource implications, when assessing longitudinal outcomes after a nutritional intervention, was also important for future studies.
The aims of this sub-study were to evaluate the effect of augmenting early EN with a 1.5 kcal/ml formula on functional outcomes and mental health, using self-perception global assessments, and disability, using employment status one year after critical illness.
Methods

Study design
This study was a prospective, observational, follow-up evaluation of patients enrolled in the TARGET feasibility study. Patients were originally enrolled from five Australian intensive care units (ICU) using either an opt-out or deferred consent process 10 . The evaluations undertaken for this study occurred between February and September 2014. Ethics approval was obtained from the Human Research Ethics Committee at each participating institution.
Patients
All patients enrolled in the TARGET feasibility study and known to be alive at day 90 were eligible for inclusion in this follow-up evaluation. Death between day 90 and one year was initially determined using state death registries and the next of kin of patients deemed to have died during this interval were not approached. All remaining patients were considered to have survived and attempts were made to contact them to obtain informed consent to participate in the follow-up study. Details of the TARGET eligibility criteria, patient population, and intervention have been reported 10 .
Study Procedures
Patients were initially mailed a letter and information sheet that explained the study, along with an opt-out slip and reply-paid addressed envelope. Two weeks elapsed before further contact was made so that patients who did not wish to be involved in this study could decline to participate. After this time, patient contact details were forwarded onto research personnel conducting the follow-up.
Two investigators (DR and LC) telephoned potentially eligible patients. These investigators were not involved in the initial study and remained blinded to treatment allocation. The study purpose was explained and verbal consent obtained. Patients were telephoned on their primary number a minimum of three times each, with at least one attempt made after-hours or on a weekend day. If contact remained unsuccessful, alternative numbers including the participant's next of kin and/or general practitioner, were sought and utilised. Questionnaires were completed over the telephone with patients or, when necessary, their appropriate proxy in a consistent order (Short Form-36 version 2 [SF -36v2] healthrelated quality of life instrument, followed by the EuroQol-5D-5L [EQ -5D -5L]generic two-part quality of life instrument followed by the employment status). For patients unable to complete follow-up by telephone, questionnaires were emailed or posted to the patient and/or designated proxy for completion.
Outcomes
Four questionnaires were completed by each consenting participant. The primary outcome was the physical function summary score derived from the SF-36v2. The SF-36v2 comprises 36 questions that yield an eight domain profile of functional health and wellbeing. While emphasis was on between group comparisons, total population data were also compared to South Australian population norms, as the latter have been published and were readily available 15 .
Secondary outcomes included the SF-36v2 mental health summary score and scores for each domain 15 , and the EQ-5D-5L, with the prevalence of issues in binary form across five dimensions of functional health, utility score, and visual analogue score for self-rated health status (range 0-100; greater score is better) measured 16 . Employment status at baseline and at one year was assessed and categorised as employed, unemployed but seeking work, or retired (either due to permanent disability or age).
Statistical analysis
SF-36v2 health survey data was recorded into the commercially available software provided by QualityMetric (Quality Metric Incorporated, Lincoln, RI, USA).
Categorical variables are reported as counts and percentages, and continuous variables are presented as mean (standard error) or median (interquartile range; IQR) as appropriate. SF-36v2 summary scores were expressed as means (standard error), EQ-5D-5L utility scores were expressed as counts and percentages, and the EQ-5D-5L visual analogue scale score was presented as the median (IQR).
Differences between groups were analysed using independent samples t-test for age, ICU admission diagnosis, APACHE II score, weight, and SF-36v2 data, Fisher's exact test for sex and employment status post illness, and Mann-Whitney test for hospital and ICU length of stay (LOS) data. Comparisons between groups on EQ-5D-5L data used Mann-Whitney (VAS) and chi-square tests (dimensions of functional health). A P-value less than 0.05 for comparisons was considered significant.
Results
Study patients
Between 90 days and one year after enrolment seven patients who received 1.5 kcal/ml formula and one patient who received 1.0 kcal/ml formula died (survivors at one year: 1.5 kcal/ml 38 versus 1.0 kcal/ml 33; P=0.55). Of the 71 survivors, and therefore eligible participants, 39 (55%) consented to participation in this study (n=23 and n=16, respectively). One patient in each group did not complete all questionnaires (see Figure 1 ).
Baseline characteristics
The average age of follow-up participants was 56 (2.3) years and 77% were men. The mean APACHE II score on ICU admission was 20 (1.4) . The median ICU LOS was 10.2 (4.9-20.3) days and the hospital LOS was 23.9 (13.3-67.7) days. There were no differences in baseline demographics between groups (see Table 1 ).
Outcomes
SF-36v2 responses
While the reported scores in patients were lower than those reported in normal populations, augmenting energy delivery during critical illness with a 1.5 kcal/ml formula was not associated with a difference in physical health component summary scores (40 [2.4] Table 2 ). Characteristics of the participants in the 12-month follow-up and participants in TARGET who were alive at 12 months but did not participate in this study.
APACHE II: Acute Physiology and Chronic Health Evaluation score, LOS: length of stay, SE: standard error, IQR: interquartile range, d: days, m: months, y: years.
(Statistical analysis conducted between groups that participated in 12-month follow-up; P values all >0.15)
EQ-5D-5L responses
Patients frequently reported issues with mobility, self-care, participation in activities, pain, and anxiety, but the administration of augmented EN was not associated with a difference in these outcomes. Patients' quality of life as quantified using the visual analogue scale was also similar (65 (40-80) versus 53 (34-79); P=0.70) (see Table 3 ).
Workforce participation
One year after critical illness there were a considerable proportion of patients newly unemployed since ICU admission. However, more patients who had received augmented EN were employed and more patients who had received routine EN were either unemployed or newly retired (Table 4 ; P=0.02). 
Discussion
This is the first study to evaluate outcomes in survivors one year after they were allocated in a randomised, double-blind fashion to an enteral feeding intervention during the early phase of critical illness. Augmenting energy delivery with 1.5 kcal/ml formula for the first ten days of ICU admission did not affect self-reported physical or mental function in patients at 12 months. While the cohort was small, and employment status was only a secondary outcome, the levels of employment were greater in patients randomised to 1.5 kcal/ml when compared to 1.0 kcal/ml formula.
The findings of this study also support current literature that survivors of critical illness are markedly impaired in terms of holistic self-assessment 23, 24 . The term Post-Intensive Care Syndrome has been suggested to describe these new, persisting or worsening problems in physical, cognitive, and mental health following critical illness that are apparent when evaluating survivors using standardised health questionnaires 18, 19, 20 . Because they have been previously used to quantify outcomes one year after a nutritional intervention 11, 12 , the SF-36v2 and EQ-5D-5L were chosen to quantify holistic self-perception.
While the intervention of 1.5 kcal/ml caused a considerable increase in energy delivery for a maximum of the first ten days of ICU admission, and was associated with numerically fewer deaths 90 days after enrolment, there did not appear to be any effect on mortality at one year. There are several plausible explanations as to why this early trend to survival benefit was not sustained. Firstly, TARGET was a feasibility study and was only powered to detect a difference in energy delivery. Studies of smaller cohorts are vulnerable to overinflating the true magnitude of treatment effects 17 , and the initial trend to a difference in mortality observed at day 90, particularly given mortality was a secondary exploratory endpoint, should be interpreted with caution. Indeed, an absence of any statistical difference in mortality observed at both 90-day and one-year timepoints indicate data are consistent. Secondly, the 1.5 kcal/ml formula was provided for a maximum of ten days and any legacy effect from the acute intervention should logically be diluted due to confounders, including nutritional provision and access to rehabilitation services, after this time 11 . Thirdly, the follow-up of patients longitudinally risks selection and loss to follow-up biases, which may diminish the accuracy of observations over time.
Despite no discernible difference in self-reported quality of life (when quantified using either the SF-36v2 or EQ-5D-5L scoring systems) there was an increase in employment status post-ICU that appeared to favour augmented EN with a 1.5 kcal/ml formula. Although promising, it is important to remain guarded against spurious inferences as, due to the multitude of potential confounders, even results of randomised controlled trials should be interpreted cautiously when evaluating longitudinal outcomes 18 . Moreover, employment status was a secondary outcome in this substudy and so the result should only be considered hypothesisgenerating and requires further evaluation in a larger cohort. This observation does, however, suggest that information other than self-reported quality of life may be important for randomised controlled trials of nutritional interventions.
It is plausible that one outcome domain, such as global selfperception, remains unaffected, whereas a separate domain, such as participation (employment status), is affected by an intervention 19 . The SF-36v2 is a self-rated quality of life instrument and is vulnerable to bias. Quality of life before the critical illness was not quantified and there may have been baseline differences between groups that were not controlled for by the randomisation process 20 , e.g. it is known that pre-existing conditions such as malignancy and chronic lung disease are associated with reductions in quality of life post-ICU admission 24 . Moreover, not only do patients adapt to their illness over time 21 , which impacts on measurement of global self-perception, but the social environment of individuals is a fundamental determinant of disability 19 . Accordingly, there may have been a true improvement in participation (e.g. employment) without improvement in perception. However, further data demonstrating improvements in other aspects of participation, such as involvement in social activities or instrumental activities of daily living, are required to conclude that there is a disconnect between domains of participation and quality of life as measured using current tools.
This study has confirmed the ability to follow up patients enrolled in a nutrition study and obtain important relevant data, via appropriately conducted telephone interviews. In preparation for the larger phase III study (ClinicalTrials.gov identifier NCT02306746) it is important to establish the capacity to follow up such patients. Limitations of this study include small participant numbers. TARGET was designed as a feasibility study to determine the effect of administering a 1.5 kcal/ml formula for a maximum of ten days on early energy delivery. Nonetheless, the consent rate for this follow-up component was lower than expected. Given the participation rate in this study, alternative techniques, such as a shorter duration to assessment and/or regular ongoing contact with participants after ICU discharge 4, 22 , may be of benefit during the larger study. In addition, post-ICU care data were not collected and such interventions are likely to be a major determinant of longitudinal outcomes 23 . Finally, validated measurements of quality of life (SF-36v2 and EQ-5D-5L) 24,25 , and enquiries regarding employment status, were conducted, and given the results other measures of participation would have been of interest.
In conclusion, while the provision of a 1.5 kcal/ml formula for a maximum of ten days in ICU augmented early energy delivery, this intervention did not influence the patients' perceived quality of life one year later. Delivery of a 1.5 kcal/ml formula was, however, associated with more patients employed at one year; but due to the limited trial size, dropouts and small number of events, this finding is of uncertain robustness and warrants further investigation in a larger trial as planned.
